

**Learn more about the  
LUCINDA Trial**

**Contact:**

**Meg Hackbarth**

Clinical Research Coordinator

**608-263-1909**

mmhackbarth@clinicaltrials.wisc.edu

[adrc.wisc.edu/lucinda](http://adrc.wisc.edu/lucinda)

**STUDY LEADERSHIP**

**Craig Atwood, PhD**

University of Wisconsin–Madison  
Madison, WI

**Tracy Butler, MD**

Weill Cornell Medicine  
New York, NY

**James Galvin, MD**

University of Miami  
Miami, FL

LUCINDA is supported by a  
grant from the  
National Institutes of Health  
ClinicalTrials.gov: NCT03649724

**SEEKING  
VOLUNTEERS  
FOR A  
RESEARCH STUDY**

**LUCINDA**

*LeUprolide + Cholinesterase  
Inhibition to reduce  
Neurologic Decline in  
Alzheimer's*





### About the study

LUCINDA is a clinical research trial to determine whether leuprolide (Eligard, an injectable medication) can slow or prevent decline in thinking abilities and functioning in women with mild cognitive impairment or Alzheimer's disease who are also taking a cholinesterase inhibitor medication such as donepezil (Aricept).

### What does the study involve?

If you are interested, a research coordinator will give you detailed information about the study. You will be asked to sign an informed consent form.

There will be approximately eight study visits spread out over one year. Study procedures include tests of thinking abilities, blood tests, two MRI scans and one PET scan to measure amyloid in the brain. There will be injection of study drug (leuprolide or placebo) four times over one year.

### What is leuprolide normally used for?

Leuprolide is approved by the FDA for treatment of prostate cancer in men, endometriosis in women, and early puberty in children. It is also commonly used in women preparing for in vitro fertilization. LUCINDA aims to *repurpose* leuprolide for Alzheimer's disease.

### Key eligibility

- ◆ Women over age 60
- ◆ Diagnosed with mild cognitive impairment or Alzheimer's disease
- ◆ Taking a cholinesterase inhibitor such as donepezil (Aricept)
- ◆ Participants must have a study partner (friend, family member or caregiver) who can accompany them to all study visits
- ◆ Detailed eligibility will be reviewed with the study team

**There is no cost to be in this study. You will be compensated for your time and effort.**